A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Phase 1
232
about 5.5 years
18+
10 sites in CA, IL, MO +3
About this study
Researchers are testing a treatment called ABBV-324 to see if it causes side effects and changes the activity of cancer. The trial will involve adult participants with either hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). Participants will receive ABBV-324 alone or in combination with lenvatinib, and doctors will monitor them for side effects and disease progression.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ABBV-324
- 2.Take Lenvatinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
lenvatinib
oral (Oral Capsule)
Primary: Number of Participants with Adverse Events (AE)s, Objective Response Rate (ORR)
Secondary: Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-324, Maximum Observed Serum Concentration (Cmax) of ABBV-324, Terminal Elimination Half-Life (t1/2) of ABBV-324, Time to Maximum Observed Serum Concentration (Tmax) of ABBV-324
Oncology